Plain-English translation of NCT07303699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether atorvastatin, a medication normally used to lower cholesterol, might help improve treatment outcomes when added to standard tuberculosis medications. Researchers want to find the right dose of this medication to use alongside standard TB treatment in future studies. You would receive standard TB drugs plus daily atorvastatin (at one of three different doses) or standard TB drugs alone, depending on which group you're assigned to.
Tuberculosis is a serious infection that is difficult to treat, and adding this medication might help people recover faster and more completely. Researchers are exploring whether this treatment approach could lead to better outcomes for TB patients.
You likely qualify if…
You likely don't qualify if…
You will receive standard TB medications for 24 weeks, and depending on your group assignment, you will also take a daily dose of the cholesterol medication for the first 16 weeks. You'll attend multiple study visits over one year, where you'll provide sputum samples, have chest X-rays, lung function tests, and blood draws to check how the medications are working in your body. After your treatment ends at 24 weeks, you'll continue to be followed for an additional 6 months to monitor your recovery.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Nigeria